Drug Profile

MTD 119

Alternative Names: MTD119; MTR-104

Latest Information Update: 16 May 2023

Price :

$50 ^*

Note:

Adis is an information provider. We do not sell or distribute actual drugs.
Final gross price and currency may vary according to local VAT and billing address.
Your purchase entitles you to full access to the information contained in our drug profile at the time of purchase.
A link to download a PDF version of the drug profile will be included in your email receipt.

At a glance

Originator Midatech
Developer Biodexa Pharmaceuticals; Dana-Farber Cancer Institute
Class Antineoplastics; Drug conjugates
Mechanism of Action Tubulin inhibitors

Orphan Drug Status

Orphan designation is assigned by a regulatory body to encourage companies to develop drugs for rare diseases.

Yes - Liver cancer
New Molecular Entity Yes

Highest Development Phases

No development reported Liver cancer

Most Recent Events

28 Jun 2020 No recent reports of development identified for preclinical development in Liver-cancer in United Kingdom
28 Jun 2020 No recent reports of development identified for preclinical development in Liver-cancer in USA
25 Jan 2019 MTD 119 licensed to China medical System in China, Hong Kong, Macau and Taiwan

You need to be a logged in or subscribed to view this content Request demo

If your organization or you do not have a subscription, try one of the following:

Contacting your organization’s admin about adding this content to your AdisInsight subscription
Buying a PDF version of any individual profile
Request a free trial

If your organization has a subscription, there are several access options, even while working remotely:

Working within your organization’s network
Login with username/password or try to access via your institution
Persisted access using your organization’s identifier stored in your user browser for 90 days

For assistance, contact us at asktheexpert.adisinsight@springer.com